NCCS joined the Alliance for Childhood Cancer in submitting comments to the Food and Drug Administration (FDA) following the January 2014 public workshop on complex issues in developing drug and biological products for rare diseases. The Alliance encouraged the FDA to consider the issues specific to pediatric cancers that may be different from other rare disease and to continue to adopt a flexible approach to risk-benefit assessment for pediatric cancer drug development. Additionally, the Alliance urged the FDA to establish clinical trial endpoints that reflect quality of life concerns.
Make An Impact
The NCCS Cancer Policy & Advocacy Team (CPAT) is a program for survivors and caregivers to learn about pressing policy issues that affect quality cancer care in order to be engaged as advocates in public policy around the needs of cancer survivors.
Together we can improve cancer care for survivors! Sign up to be the first to know about cancer policy issues and ways to take action
- Get Involved
- COVID-19 Resources for Cancer Survivors
- Survivorship Checklist
- Cancer Survival Toolbox
- Survivorship Champions
- Cancer Convos Podcast
- Taking Charge of Your Care
- Care Planning for Cancer Survivors
- Tools For Care Providers
- Order Our Resources
- 2021 State of Survivorship Survey Results Briefing
- Ellen L. Stovall Award
- From Shadows to Life: A Biography of the Cancer Survivorship Movement
- Cancer Policy and Advocacy Team (CPAT) Symposium 2021
- Cancer Policy Roundtable (CPR)
- Contact Us
Copyright © 1995-2021 by the National Coalition for Cancer Survivorship
National Coalition for Cancer Survivorship, NCCS, Cancer Survival Toolbox, and related Logos are registered in the United States as trademarks of the National Coalition for Cancer Survivorship.